Aberrant β-catenin activity in hepatoid adenocarcinoma of the stomach.
CONCLUSION: Our findings establish β-catenin as a useful marker that can distinguish HAS from CGA and may improve the early diagnosis to guide the appropriate and timely treatment of HAS patients.
PMID: 32442081 [PubMed - as supplied by publisher]
Source: Current Molecular Medicine - Category: Molecular Biology Authors: Wang N, Kong R, Han W, Lu J Tags: Curr Mol Med Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Gastric (Stomach) Cancer | Gastroenterology | Hepatocellular Carcinoma | Liver Cancer | Molecular Biology | Statistics | Study